28. Systemic amyloidosis Clinical trials / Disease details
Clinical trials : 261 / Drugs : 276 - (DrugBank : 81) / Drug target genes : 68 - Drug target pathways : 178
Showing 1 to 10 of 83 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04984330 (ClinicalTrials.gov) | March 2022 | 29/7/2021 | Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease | Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease | Amyloid;Amyloidosis;AL Amyloidosis | Drug: Selinexor;Drug: Dexamethasone | Weill Medical College of Cornell University | Karyopharm Therapeutics Inc | Recruiting | 18 Years | N/A | All | 10 | Early Phase 1 | United States |
| 2 | NCT04847453 (ClinicalTrials.gov) | September 14, 2021 | 15/4/2021 | Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory ... | A Phase 1/1a Study of Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for Relapsed/Refractory Light Chain Amyloidosis A Phase 1/1a Study of Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for Relapsed/Refracto ... | Recurrent AL Amyloidosis;Refractory AL Amyloidosis | Procedure: Bone Marrow Aspiration and Biopsy;Drug: Dexamethasone;Drug: Ixazomib Citrate;Drug: Venetoclax Procedure: Bone Marrow Aspiration and Biopsy;Drug: Dexamethasone;Drug: IxazomibCitrate;Drug: Venetoc ... | National Cancer Institute (NCI) | NULL | Recruiting | 18 Years | N/A | All | 6 | Phase 1 | United States |
| 3 | NCT04754945 (ClinicalTrials.gov) | April 28, 2021 | 9/2/2021 | Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis | Slow-Go Strategy for High Risk AL Amyloidosis: Isatuximab for Upfront Therapy | AL Amyloidosis | Drug: Bortezomib;Drug: Cyclophosphamide;Drug: Dexamethasone;Biological: Isatuximab | Emory University | Sanofi;National Cancer Institute (NCI) | Recruiting | 18 Years | N/A | All | 25 | Phase 1 | United States |
| 4 | NCT04270175 (ClinicalTrials.gov) | April 14, 2021 | 12/2/2020 | Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Pa ... | Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Pa ... | Amyloid;AL Amyloidosis;Refractory AL Amyloidosis | Drug: Daratumumab;Drug: Pomalidomide;Drug: Dexamethasone | Weill Medical College of Cornell University | Janssen Scientific Affairs, LLC | Recruiting | 18 Years | N/A | All | 21 | Phase 2 | United States |
| 5 | NCT04504825 (ClinicalTrials.gov) | August 25, 2020 | 20/7/2020 | A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amy ... | A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment Naïve Patients With Mayo Stage IIIb AL Amyloidosis A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasm ... | AL Amyloidosis | Drug: CAEL-101;Other: Placebo;Drug: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen Drug: CAEL-101;Other: Placebo;Drug: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen ... | Caelum Biosciences, Inc. | Alexion Pharmaceuticals | Recruiting | 18 Years | N/A | All | 111 | Phase 3 | United States;Australia;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom United States;Australia;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Feder ... |
| 6 | NCT04512235 (ClinicalTrials.gov) | August 25, 2020 | 10/8/2020 | A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amy ... | A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment Naïve Patients With Mayo Stage IIIa AL Amyloidosis A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasm ... | AL Amyloidosis | Drug: CAEL-101;Other: Placebo;Drug: cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen Drug: CAEL-101;Other: Placebo;Drug: cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen ... | Caelum Biosciences, Inc. | Alexion Pharmaceuticals | Recruiting | 18 Years | N/A | All | 267 | Phase 3 | United States;Australia;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Federation;Spain;United Kingdom United States;Australia;Belgium;Canada;France;Germany;Greece;Israel;Italy;Japan;Poland;Russian Feder ... |
| 7 | NCT04115956 (ClinicalTrials.gov) | August 6, 2020 | 29/8/2019 | A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglob ... | An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients With AL Amyloidosis Following at Least One Prior Line of Therapy An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients With AL Amyloidosis Follo ... | AL Amyloidosis | Drug: Melphalan-Flufenamide (Melflufen);Drug: Dexamethasone | Oncopeptides AB | PRA Health Sciences | Terminated | 18 Years | N/A | All | 6 | Phase 1/Phase 2 | United States;Czechia;France;Germany;Greece;Israel;Norway;Spain;United Kingdom;Italy;Poland |
| 8 | NCT04304144 (ClinicalTrials.gov) | March 18, 2020 | 28/2/2020 | A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis | CAEL101-203: A Phase 2, Open-label, Multicenter Dose Selection Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis CAEL101-203: A Phase 2, Open-label, Multicenter Dose Selection Study to Evaluate the Safety and Tole ... | AL Amyloidosis | Drug: CAEL-101;Drug: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD);Drug: Daratumumab | Caelum Biosciences | NULL | Active, not recruiting | 18 Years | N/A | All | 25 | Phase 2 | United States |
| 9 | EUCTR2018-002761-19-DE (EUCTR) | 06/03/2020 | 12/08/2019 | An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients with AL Amyloidosis Following at Least One Prior Line of Therapy An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients with AL Amyloidosis Follo ... | An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients with AL Amyloidosis Following at Least One Prior Line of Therapy An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients with AL Amyloidosis Follo ... | Patients with AL Amyloidosis MedDRA version: 20.0;Level: PT;Classification code 10002022;Term: Amyloidosis;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] Patients with AL Amyloidosis MedDRA version: 20.0;Level: PT;Classification code 10002022;Term: Amylo ... | Product Name: Melflufen INN or Proposed INN: melphalan fulfenamide hydrochloride Other descriptive name: MELFLUFEN Trade Name: Dexamethasone 4 mg JENAPHARM Product Name: Dexamethasone Product Code: H02AB02 INN or Proposed INN: DEXAMETHASONE Product Name: Melflufen INN or Proposed INN: melphalanfulfenamide hydrochloride Other descriptive name ... | Oncopeptides AB | NULL | Not Recruiting | Female: yes Male: yes | 46 | Phase 2 | France;United States;Czechia;Czech Republic;Greece;Spain;Poland;Israel;Norway;Germany;United Kingdom;Italy France;United States;Czechia;Czech Republic;Greece;Spain;Poland;Israel;Norway;Germany;United Kingdom ... | ||
| 10 | EUCTR2018-002761-19-ES (EUCTR) | 05/02/2020 | 09/08/2019 | It is an early clinical trial to assess a new drug (Melflufen) when giventogether with a steroid (Dexamethasone) in the treatment of patients with a disease called the AL Amyloidosis.Patients should also have received treatment in the past for the disease. It is an early clinical trial to assess a new drug (Melflufen) when giventogether with a steroid (De ... | An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients with AL Amyloidosis Following at Least One Prior Line of Therapy An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients with AL Amyloidosis Follo ... | Patients with AL Amyloidosis MedDRA version: 20.0;Level: PT;Classification code 10002022;Term: Amyloidosis;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] Patients with AL Amyloidosis MedDRA version: 20.0;Level: PT;Classification code 10002022;Term: Amylo ... | Product Name: Melflufen INN or Proposed INN: melphalan fulfenamide hydrochloride Other descriptive name: MELFLUFEN Trade Name: Dexamethasone 4 mg JENAPHARM Product Name: Dexamethasone Product Code: H02AB02 INN or Proposed INN: DEXAMETHASONE Product Name: Melflufen INN or Proposed INN: melphalanfulfenamide hydrochloride Other descriptive name ... | Oncopeptides AB | NULL | Not Recruiting | Female: yes Male: yes | 46 | Phase 1;Phase 2 | United States;France;Czech Republic;Greece;Poland;Spain;Israel;Norway;Germany;United Kingdom;Italy |